Michael Mikola
Internal Medicine · Mt Pleasant, SCNPI 1013969393
Payments from drug & device makers
Across 235 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$899
- AbbVie$734
- AstraZeneca$646
- Amgen$504
- Bayer$267
- Pfizer$227
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,886100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $899 |
| AbbVie(2 entities) | 34 | $734 |
| AstraZeneca | 24 | $646 |
| Amgen | 23 | $504 |
| Bayer | 6 | $267 |
| Pfizer | 19 | $227 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $211 |
| Boehringer Ingelheim | 11 | $155 |
| Merck | 13 | $145 |
| Amarin Pharma, Inc. | 8 | $106 |
| E.r. Squibb & Sons, L.L.C. | 6 | $99 |
| Idorsia Pharmaceuticals US Inc | 5 | $97 |
| Lilly USA, LLC | 6 | $86 |
| Shire North American Group Inc | 7 | $85 |
| Johnson & Johnson | 5 | $69 |
| Medtronic | 1 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Abbott | 3 | $56 |
| Novartis | 4 | $51 |
| Hikma Pharmaceuticals USA | 4 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| GSK | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Tolmar, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Vivus LLC | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,909 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $119,379 |
| EliquisApixaban | 70 | $73,795 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 64 | $54,400 |
| RybelsusSemaglutide | 39 | $49,220 |
| Xigduo XrDapaglifloz Propaned/Metformin | 58 | $45,556 |
| MounjaroTirzepatide | 39 | $40,164 |
| Repatha SureclickEvolocumab | 39 | $27,500 |
| MyrbetriqMirabegron | 22 | $25,008 |
| FarxigaDapagliflozin Propanediol | 19 | $24,501 |
| WegovySemaglutide | 15 | $19,477 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,189 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $13,250 |
| JardianceEmpagliflozin | 12 | $13,087 |
| NexlizetBempedoic Acid/Ezetimibe | 25 | $12,774 |
| XiidraLifitegrast | 11 | $7,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $899 | $188,075163 claims |
| PfizerEliquis | $227 | $73,79570 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $155 | $67,48776 claims |
| Lilly USA, LLCMounjaro | $86 | $40,16439 claims |
| AstraZenecaFarxiga | $646 | $24,50119 claims |
| GSKTrelegy Ellipta | $37 | $16,18920 claims |
| Esperion Therapeutics, Inc.Nexlizet | $20 | $12,77425 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $211 | $7,06812 claims |
| AbbVieSynthroid | $734 | $2,09621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Mt Pleasant
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Susan DattaMt Pleasant$76K
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.